Assessment of p16, p21, and p27 in granulocytic differentiation of human promyelocytic HL-60 cell line.
Navakauskiene
Ruta
R
Institute of Biochemistry, Laboratory of Developmental Biology, Mokslininku 12, 2600 Vilnius, Lithuania. ruta.navakauskiene@bchi.lt
Treigyte
Grazina
G
Gineitis
Arunas
A
Magnusson
Karl-Eric
KE
D002454:Cell Differentiation / Q000502:physiology*; D002455:Cell Division / Q000187:drug effects; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000378:metabolism*; D050759:Cyclin-Dependent Kinase Inhibitor p21; D018844:Cyclin-Dependent Kinases / Q000378:metabolism*; D016213:Cyclins / Q000378:metabolism*; D006098:Granulocytes / Q000166:cytology*; D018922:HL-60 Cells; D006801:Humans; D007700:Kinetics; D015473:Leukemia, Promyelocytic, Acute; D008840:Microfilament Proteins / Q000378:metabolism*; D009124:Muscle Proteins; D014212:Tretinoin / Q000494:pharmacology
C493956:CDKN1A protein, human; D019941:Cyclin-Dependent Kinase Inhibitor p16; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins; D008840:Microfilament Proteins; D009124:Muscle Proteins; C058992:Tagln protein, mouse; D014212:Tretinoin; D018844:Cyclin-Dependent Kinases